A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.
Saved in:
| Title: | A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. |
|---|---|
| Authors: | Emran AA; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Tseng HY; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Gunatilake D; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Cook SJ; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Ahmed F; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Wang S; Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, Australia., Hersey P; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Gallagher SJ; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Tiffen JC; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. Electronic address: j.tiffen@centenary.org.au. |
| Source: | The Journal of investigative dermatology [J Invest Dermatol] 2021 Sep; Vol. 141 (9), pp. 2238-2249.e12. Date of Electronic Publication: 2021 Mar 26. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
